Semorinemab Fails to Slow Alzheimer Disease Progression in Phase 2 Trial - Neurology Advisor

In a randomized clinical trial, researchers determined the safety and efficacy of semorinemab, a monoclonal anti-tai antibody, in prodromal to mild AD.

Semorinemab was well tolerated among patients with prodromal to mild Alzheimer disease (AD), but it did not significantly decrease cerebral tau accumulation compared with placebo. These are the findi… [+3596 chars]

full article...